AI assistant
AVECHO BIOTECHNOLOGY LIMITED — Capital/Financing Update 2021
Feb 15, 2021
64468_rns_2021-02-15_9cfc8cb2-b8de-4707-803f-899e0ea04ce6.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Update Summary
Entity name
AVECHO BIOTECHNOLOGY LIMITED
Announcement Type
Update to previous announcement
Date of this announcement
Tuesday February 16, 2021
Reason for update to a previous announcement
Update to the final number of shares to be issued and update to the issue date.
Refer to next page for full details of the announcement
Proposed issue of securities
1 / 8
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 1 - Entity and announcement details
1.1 Name of +Entity
AVECHO BIOTECHNOLOGY LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
1.2 Registered Number Type Registration Number ABN 32056482403
1.3 ASX issuer code
AVE
1.4 The announcement is
==> picture [8 x 9] intentionally omitted <==
Update/amendment to previous announcement
1.4a Reason for update to a previous announcement
Update to the final number of shares to be issued and update to the issue date.
1.4b Date of previous announcement(s) to this update
Wednesday February 10, 2021
1.5 Date of this announcement
Tuesday February 16, 2021
1.6 The Proposed issue is:
==> picture [8 x 9] intentionally omitted <==
A placement or other type of issue
Proposed issue of securities
2 / 8
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 - Are any of the following approvals required for the placement or other type of issue? +Security holder approval Court approval Lodgement of court order with +ASIC ACCC approval FIRB approval Another approval/condition external to the entity
==> picture [8 x 8] intentionally omitted <==
No
Part 7B - Issue details
Is the proposed security a 'New Will the proposed issue of this class' (+securities in a class that is +security include an offer of not yet quoted or recorded by ASX) attaching +securities? or an 'Existing class' (additional Yes securities in a class that is already quoted or recorded by ASX)? Existing class
Details of +securities proposed to be issued
ASX +security code and description
AVE : ORDINARY FULLY PAID
Number of +securities proposed to be issued
229,999,999
Reason for the update of 'Maximum Number of +securities proposed to be issued'
Following finalisation of the allotment list, 229,999,999 Fully Paid Ordinary Shares are being issued.
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration? Yes
In what currency is the cash What is the issue price per consideration being paid? +security? AUD - Australian Dollar AUD 0.02200
Proposed issue of securities
3 / 8
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes
Attaching +Security
Is the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)? New class
Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX)
Details of attaching +securities proposed to be issued
ISIN Code (if Issuer is a foreign company and +securities are non CDIs)
Have you received confirmation from ASX that the terms Will the entity be seeking quotation of the 'new' class of of the proposed +securities are appropriate and +securities on ASX? equitable under listing rule 6.1? Yes No ASX +security code +Security description New class-code to be confirmed Options at an exercise price of $0.035 each, expiring on 31 December 2023.
+Security type
Options
Number of +securities proposed to be issued
115,000,000
Reason for the update of 'Maximum Number of +securities proposed to be issued'
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration? No
Please describe the consideration being provided for the +securities
Nil - attaching Options to the Placement Shares.
Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities
Will all the +securities issued in this class rank equally in all respects from their issue date? Yes
Proposed issue of securities
4 / 8
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Options details
+Security currency
AUD - Australian Dollar
Exercise price AUD 0.0350
Expiry date Sunday December 31, 2023
Details of the type of +security that will be issued if the option is exercised
AVE : ORDINARY FULLY PAID
Number of securities that will be issued if the option is exercised
One AVE Share for each AVE Option exercised.
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.
Please refer to the ASX Announcement lodged on 10 February 2021.
Is the proposed security a 'New Will the proposed issue of this class' (+securities in a class that is +security include an offer of not yet quoted or recorded by ASX) attaching +securities? or an 'Existing class' (additional No securities in a class that is already quoted or recorded by ASX)? New class
Details of +securities proposed to be issued
ISIN Code (if Issuer is a foreign company and +securities are non CDIs)
Have you received confirmation from Will the entity be seeking quotation ASX that the terms of the proposed of the 'new' class of +securities on +securities are appropriate and ASX? equitable under listing rule 6.1? Yes No ASX +security code +Security description New class-code to be confirmed Options at an exercise price of $0.035 each, expiring on 31 December 2023.
+Security type
Options
Number of +securities proposed to be issued
7,500,000
Proposed issue of securities
5 / 8
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
==> picture [538 x 503] intentionally omitted <==
----- Start of picture text -----
Reason for the update of 'Maximum Number of +securities proposed to be issued'
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
No
Please describe the consideration being provided for the +securities
Nil - Issued as part of the Lead Manager's fees.
Please provide an estimate of the AUD equivalent of the consideration being
provided for the +securities
Will all the +securities issued in this class rank equally in all respects from
their issue date?
Yes
Options details
+Security currency Exercise price Expiry date
AUD - Australian Dollar AUD 0.0350 Sunday December 31, 2023
Details of the type of +security that will be issued if the option is exercised
AVE : ORDINARY FULLY PAID
Number of securities that will be issued if the option is exercised
One AVE Share for each AVE Option exercised.
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities
proposed to be issued or provide the information by separate announcement.
Please refer to the ASX Announcement lodged on 10 February 2021.
----- End of picture text -----
Part 7C - Timetable
7C.1 Proposed +issue date
Tuesday February 16, 2021
Part 7D - Listing Rule requirements
Proposed issue of securities
6 / 8
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? No
7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? Yes
7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?
72,110,531 Fully Paid Ordinary Shares. 115,000,000 Options attached to the New Shares (1:2 basis).
7,500,000 Options to Peak Asset Management.
7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? Yes
7D.1c ( i ) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?
157,889,468 Fully Paid Ordinary Shares.
7D.1c ( ii ) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate
It was considered that the Placement was the most cost-efficient and expedient method available to the Company at the time for raising the funds required by the Company to achieve its objectives, given the funding certainty, investor enquiry and the pricing achieved under the Placement.
7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? No
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No
7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue? Yes
7E.1a Who is the lead manager/broker?
Peak Asset Management
7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?
For the whole capital raise: 1% Management Fee on the entire raise, 6% capital raising fee for funds raised by the Broker, and 7.5 million unlisted Options at an exercise price of $0.035 each, expiring on 31 December 2023.
7E.2 Is the proposed issue to be underwritten?
==> picture [8 x 9] intentionally omitted <==
Yes
7E.2a Who are the underwriter(s)?
Peak Asset Management
Proposed issue of securities
7 / 8
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
7E.2b What is the extent of the underwriting (ie the amount or proportion of the proposed issue that is underwritten)?
$4,000,000.
7E.2c What fee, commission or other consideration is payable to them for acting as underwriter(s)?
For the whole capital raise: 1% Management Fee on the entire raise, 6% capital raising fee for funds raised by the Broker, and 7.5 million unlisted Options at an exercise price of $0.035 each, expiring on 31 December 2023.
7E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated.
Company can terminate the agreement at any time, following the conclusion of the Placement or if Peak Asset Management fails to raise the minimum amount of $4,000,000.
7E.3 Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed issue? No
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue None.
Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
To advance pharmaceutical cannabinoid program.
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No
7F.2 Any other information the entity wishes to provide about the proposed issue
N/A
Proposed issue of securities
8 / 8